Sanofi Pasteur MSD Limited

Mallards Reach, Bridge Avenue, Maidenhead, Berkshire, SL6 1QP
Telephone: +44 (0)1628 785 291
Fax: +44 (0)1628 671 722
Medical Information Direct Line: +44 (0)1628 587 693
Medical Information e-mail: medinfo@spmsd.com
Medical Information Fax: +44 (0)1628 635 072

Patient Information Leaflet last updated on the eMC: 09/02/2012
PIL REPEVAX

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 09/02/2012 and displayed until Current
Reasons for adding or updating:
  • Change to side-effects
  • Change to dosage and administration
Updated on 14/07/2011 and displayed until 09/02/2012
Reasons for adding or updating:
  • Change to Further Information section
  • Change to date of revision
  • Change to warnings or special precautions for use
  • Change to side-effects
Updated on 20/05/2010 and displayed until 14/07/2011
Reasons for adding or updating:
  • Change to date of revision
  • Change to warnings or special precautions for use
  • Change of contra-indications
  • Change to side-effects
  • Change to dosage and administration
Updated on 19/08/2009 and displayed until 20/05/2010
Reasons for adding or updating:
  • Improved Electronic Presentation
Updated on 18/08/2009 and displayed until 19/08/2009
Reasons for adding or updating:
  • Change due to harmonisation of PIL.
  • Change to side-effects
Updated on 13/05/2008 and displayed until 18/08/2009
Reasons for adding or updating:
  • Change of trade or generic name
  • Change of contra-indications
  • Change to side-effects
  • Change to information about pregnancy or lactation
Updated on 20/04/2006 and displayed until 13/05/2008
Reasons for adding or updating:
  • New PIL for eMC ie a PIL for an existing product but one that is new to the eMC